cis-(+)-3-Methyl-4-(phenylaMino)-1-(phenylMethyl)-4-piperidinecarbonitrile

We are cis-(+)-3-Methyl-4-(phenylaMino)-1-(phenylMethyl)-4-piperidinecarbonitrile CAS:147292-24-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:cis-(+)-3-Methyl-4-(phenylaMino)-1-(phenylMethyl)-4-piperidinecarbonitrile
CAS.NO:  147292-24-8
Synonyms:
cis-(+)-3-Methyl-4-(phenylaMino)-1-(phenylMethyl)-4-piperidinecarbonitrile

Molecular Formula: C20H23N3
Molecular Weight: 305.41672

Physical and Chemical Properties:
Density: /
Boiling point: /
Melting point:133-136° C (lit.)
Flash point: /
Refractive index: /

Specification:
Appearance: White to Pale Yellow Solid
Purity:≥98%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Fentanyl citrate  CAS:990-73-8
Intermediates of Fentanyl hydrochloride CAS:1443-54-5

Related News: Most foreign drugmakers offered Beijing the lowest prices globally in a recent round of negotiations in order to get some of their new products included in national insurance program, a move that will help them gain access to more patients in less-affluent cities, officials said on Thursday.115290-81-8 Most foreign drugmakers offered Beijing the lowest prices globally in a recent round of negotiations in order to get some of their new products included in national insurance program, a move that will help them gain access to more patients in less-affluent cities, officials said on Thursday.9-fluorononan-1-ol CAS:463-24-1 Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).Ácido 2- (trifluorometil) acrílico CAS:381-98-6 Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).In the TOP50 list of API export companies in 2017, the geographical clustering of advantageous companies is still obvious. For example, Huahai and Pluo in Zhejiang, CSPC of Hebei, Xinhua Pharmaceutical and Xinfa Pharmaceutical of Shandong rank well. Rank.